NewLink Genetics is a biopharmaceutical company applying innovative techniques in cancer biology to produce new diagnostic and therapeutic agents to improve the lives of cancer patients. NewLink Genetics has several cutting edge, patented technologies already in its clinical development pipeline. Dr. Charles Link, founder of NewLink Genetics has been investigating HyperAcute® technology as a novel method for cancer treatment since 1995. HyperAcute® is currently in clinical trials at the National Cancer Institute and other clinical centers as indicated below.